{"id":"NCT01358760","sponsor":"EndoCeutics Inc.","briefTitle":"Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2012-04","completion":"2012-05","firstPosted":"2011-05-24","resultsPosted":"2017-06-12","lastUpdate":"2017-06-12"},"enrollment":450,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Vaginal Atrophy"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"DHEA","otherNames":["Prasterone, Dehydroepiandrosterone"]},{"type":"DRUG","name":"DHEA","otherNames":["Prasterone, Dehydroepiandrosterone"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"0.25% DHEA","type":"EXPERIMENTAL"},{"label":"0.5% DHEA","type":"EXPERIMENTAL"}],"summary":"The purpose of this Phase III trial is to evaluate the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy.","primaryOutcome":{"measure":"Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":60.66,"sd":3.4},{"arm":"0.25% DHEA","deltaMin":56.74,"sd":3.69},{"arm":"0.50% DHEA","deltaMin":59.54,"sd":3.41}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":42,"countries":["United States","Canada"]},"refs":{"pmids":["25511551","25968836"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":150},"commonTop":["Urinary tract infection","Nasopharyngitis"]}}